Cargando…
Defining medication adherence in individual patients
BACKGROUND: The classification of patients as adherent or non-adherent to medications is typically based on an arbitrary threshold for the proportion of prescribed doses taken. Here, we define a patient as pharmacokinetically adherent if the serum drug levels resulting from his/her pattern of medica...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494613/ https://www.ncbi.nlm.nih.gov/pubmed/26170639 http://dx.doi.org/10.2147/PPA.S86249 |
_version_ | 1782380129493712896 |
---|---|
author | Morrison, Alan Stauffer, Melissa E Kaufman, Anna S |
author_facet | Morrison, Alan Stauffer, Melissa E Kaufman, Anna S |
author_sort | Morrison, Alan |
collection | PubMed |
description | BACKGROUND: The classification of patients as adherent or non-adherent to medications is typically based on an arbitrary threshold for the proportion of prescribed doses taken. Here, we define a patient as pharmacokinetically adherent if the serum drug levels resulting from his/her pattern of medication-taking behavior remained within the therapeutic range. METHODS: We used pharmacokinetic modeling to calculate serum drug levels in patients whose patterns of dosing were recorded by a medication event monitoring system. Medication event monitoring system data were from a previously published study of seven psoriasis patients prescribed 40 mg subcutaneous adalimumab at 14-day intervals for 1 year. Daily serum concentrations of adalimumab were calculated and compared with a known therapeutic threshold. RESULTS: None of the seven patients took adalimumab precisely every 14 days. Three patients who took adalimumab at intervals of 6–26 days could be classified as pharmacokinetically adherent, because their daily adalimumab serum concentration never fell below the therapeutic threshold. The four other patients, who took adalimumab at intervals of 7–93 days, could be classified as pharmacokinetically non-adherent, because their adalimumab serum concentration fell below the therapeutic threshold on 3.5%–71.3% of days. CONCLUSION: Patients with varying patterns of adalimumab dosing could be classified as pharmacokinetically adherent or non-adherent according to whether or not their serum drug concentrations remained within the therapeutic range. |
format | Online Article Text |
id | pubmed-4494613 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-44946132015-07-13 Defining medication adherence in individual patients Morrison, Alan Stauffer, Melissa E Kaufman, Anna S Patient Prefer Adherence Original Research BACKGROUND: The classification of patients as adherent or non-adherent to medications is typically based on an arbitrary threshold for the proportion of prescribed doses taken. Here, we define a patient as pharmacokinetically adherent if the serum drug levels resulting from his/her pattern of medication-taking behavior remained within the therapeutic range. METHODS: We used pharmacokinetic modeling to calculate serum drug levels in patients whose patterns of dosing were recorded by a medication event monitoring system. Medication event monitoring system data were from a previously published study of seven psoriasis patients prescribed 40 mg subcutaneous adalimumab at 14-day intervals for 1 year. Daily serum concentrations of adalimumab were calculated and compared with a known therapeutic threshold. RESULTS: None of the seven patients took adalimumab precisely every 14 days. Three patients who took adalimumab at intervals of 6–26 days could be classified as pharmacokinetically adherent, because their daily adalimumab serum concentration never fell below the therapeutic threshold. The four other patients, who took adalimumab at intervals of 7–93 days, could be classified as pharmacokinetically non-adherent, because their adalimumab serum concentration fell below the therapeutic threshold on 3.5%–71.3% of days. CONCLUSION: Patients with varying patterns of adalimumab dosing could be classified as pharmacokinetically adherent or non-adherent according to whether or not their serum drug concentrations remained within the therapeutic range. Dove Medical Press 2015-07-01 /pmc/articles/PMC4494613/ /pubmed/26170639 http://dx.doi.org/10.2147/PPA.S86249 Text en © 2015 Morrison et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
spellingShingle | Original Research Morrison, Alan Stauffer, Melissa E Kaufman, Anna S Defining medication adherence in individual patients |
title | Defining medication adherence in individual patients |
title_full | Defining medication adherence in individual patients |
title_fullStr | Defining medication adherence in individual patients |
title_full_unstemmed | Defining medication adherence in individual patients |
title_short | Defining medication adherence in individual patients |
title_sort | defining medication adherence in individual patients |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4494613/ https://www.ncbi.nlm.nih.gov/pubmed/26170639 http://dx.doi.org/10.2147/PPA.S86249 |
work_keys_str_mv | AT morrisonalan definingmedicationadherenceinindividualpatients AT stauffermelissae definingmedicationadherenceinindividualpatients AT kaufmanannas definingmedicationadherenceinindividualpatients |